- The FDA has accepted for review BeyondSpring Inc's BYSI marketing application seeking approval for the use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
- Under the priority review, the target action date is set for November 30.
- Plinabulin acts as a selective immunomodulating microtubule-binding agent (SIMBA), with immune anti-cancer activities and broad activities to prevent CIN across chemotherapy and cancer types.
- Price Action: BYSI shares are up 11.4% at $11.55 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
